H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $14.00 price target on Ocular Therapeutix (NASDAQ: OCUL).

The analyst commented: "Yesterday, Ocular Therapeutix announced that the Phase 3 SOL-1 trial of AXPAXLI in wet AMD is expected to be fully enrolled with all patients randomized by the end of 2024 due to strong interest from investigators and patients. This is meaningfully ahead of prior guidance of enrollment completion by 1Q25. Management now expects to report topline data from the SOL-1 trial in 4Q25. In our view, the accelerated timeline denotes strong market demand for a durable treatment option for wet AMD with reduced treatment burden. We note that the all patients would enroll into the SOL-R trial once SOL-1 completes enrollment. Therefore, accelerated timeline for SOL-1 could expedite enrollment for SOL-R. In the wake of this update, we reiterate our Buy rating and $14 PT."

For an analyst ratings summary and ratings history on Ocular Therapeutix click here. For more ratings news on Ocular Therapeutix click here.

Shares of Ocular Therapeutix closed at $10.23 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Datavault AI (DVLT) Will Acquire CyberCatch in an All-Cash Transaction